Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
Program (Cell Type) Indication CAR Target(s) Research Preclinical Phase 1 Partner
FT576 (iNK) Multiple Myeloma BCMA


FT522 (iNK) B-Cell Lymphoma CD19, 41BB


FT819 (iT) B-Cell Malignancies CD19


FT825 (iT) Solid tumors HER2


Undisclosed Solid tumors Undisclosed


Ono Logo
Autoimmune Disorders
FT819 (iT) Systemic Lupus Erythmatosus CD19


FT522 (iNK) Undisclosed CD19, 41BB



Program Indication CAR Targert(s) Phase
FT576 (iNK) Multiple Myeloma BCMA Ph 1
FT222 (iNK) B-Cell Lymphoma CD19, 41BB PreClin
FT819 (iT) B-Cell Malignancies CD19 Ph 1
FT825 (iT) Solid tumors HER2 Ph 1
Undisclosed Solid tumors Undisclosed Research

Autoimmune Disorders

Program Indication CAR Target(s) Phase
FT819 (iT) Systemic Lupus Erythmatosu CD19 Ph 1
FT222 (iNK) Undisclosed CD19, 41BB Preclin

iPSC = induced pluripotent stem cell    iNK = iPSC-derived NK Cell    iT = iPSC-derived T cell    CAR = chimeric antigen receptor